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Abstract
Adolescents and young adults (AYAs, ages 15–40 years) with cancer have not experienced
survival improvements to the same extent as younger and older patients. We compared changes in
survival following myeloablative allogeneic hematopoietic cell transplantation (HCT) for acute
lymphoblastic leukemia (ALL) among children (N=981), AYAs (N=1218) and older adults
(N=469) who were transplanted over three time periods: 1990–1995, 1996–2001 and 2002–2007.
Five-year survival varied inversely with age group. Survival improved over time in AYAs and
paralleled that seen in children; however, overall survival did not change over time for older
adults. Survival improvements were primarily related to lower rates of early treatment related
mortality in the most recent era. For all cohorts, relapse rates did not change over time. A subset of
222 AYAs between the ages of 15–25 at 46 pediatric or 49 adult centers were also analyzed to
describe differences by center type. In this subgroup, there were differences in transplant practices
among pediatric and adult centers, although HCT outcomes did not differ by center type. Survival
for AYAs undergoing myeloablative allogeneic HCT for ALL improved at a similar rate as
survival for children.
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Introduction
Adolescents and young adults (AYAs, ages 15–40) with cancer are considered to be a
vulnerable subgroup by the National Cancer Institute, in part because survival improvements
over time have lagged behind survival improvements for older and younger patients with
cancer (Bleyer A, 2007; Wood WA, 2011). AYAs with acute lymphoblastic leukemia (ALL)
have garnered particular interest because of apparent survival disparities related to treatment
in pediatric versus adult oncology settings. Several retrospective analyses have demonstrated
superior survival for AYAs with ALL treated on pediatric protocols, such as a Children’s
Cancer Group (CCG) versus Cancer and Leukemia Group B (CALGB) comparison in which
5-year event free survival and overall survival rates favored AYAs treated on pediatric
studies (63% versus 34%, p<0.001 and 67% versus 46%, p<0.001 respectively) (Stock W,
2008). The reasons for these disparities are not entirely clear, though some have suggested
differences in the type and amount of anti-leukemic drugs in pediatric versus adult treatment
protocols (Stock W, 2010). Others have also pointed to differences in the way care is
delivered to AYAs in pediatric versus adult settings, favoring improved access to care
through insurance coverage (Kantarjian HM, 2009), better adherence, and a higher
proportion of on-time receipt of therapy in the pediatric setting (Schafer, 2011).
In hematopoietic cell transplantation (HCT), outcomes have improved over time, in part
because of improvements in supportive care and a corresponding reduction in transplant-
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related mortality [Gooley T, 2010; Hahn T, 2013]. However, few studies specifically
addressed outcomes among AYAs undergoing HCT (Burke MJ, BBMT 2013), and it is
unclear whether the benefits of improvements in supportive care have been realized equally
in the vulnerable AYA population. For these reasons, we sought to determine whether
outcomes for AYAs following myeloablative allogeneic HCT for ALL have improved to a
similar degree as those among older and younger patients. Further, we wished to determine
whether significant differences existed in care delivery characteristics associated with
pediatric versus adult HCT settings for AYAs with ALL. We analyzed data reported to the
Center for International Blood and Marrow Transplant Research (CIBMTR) to address these
questions.
Methods
Data Source and Patients
The CIBMTR is a voluntary working group of more than 450 transplantation centers
worldwide that contribute detailed data on allogeneic and autologous HCTs to a Statistical
Center at the Medical College of Wisconsin in Milwaukee and the National Marrow Donor
Program (NMDP) Coordinating Center in Minneapolis. Centers are required to report all
consecutive transplantations and patients are followed over time, with yearly follow-up.
Computerized checks for discrepancies, physicians’ review of submitted data, and on-site
audits of participating centers ensure data quality. Observational studies conducted by the
CIBMTR are performed in compliance with the Privacy Rule (HIPAA) as a Public Health
Authority and in compliance with all applicable federal regulations pertaining to the
protection of human research participants as determined by continuous review of the
Institutional Review Board of the NMDP.
For this study, we included patients who had received their first allogeneic HCT for ALL
using either an HLA-identical sibling donor (matched sibling donor, MSD) or unrelated
donor (URD) from 1990–2007 at a transplantation center in the United States. Only patients
who underwent transplantation following myeloablative conditioning and were in either first
or second complete remission (CR) were included in this analysis. Recipients of umbilical
cord blood grafts were excluded. Patients were divided into three groups based on age at
transplantation: children (<15 years), AYAs (15–40 years) and older adults (>40 years) to
match the recommended NCI Progress Review Group age definition for AYAs (Adolescent
and Young Adult Oncology Progress Review Group, 2006).
Outcomes and study definitions
The primary objective of this study was to compare change over time in rates of overall
survival (OS), leukemia-free survival (LFS), relapse, and treatment related mortality (TRM)
among children, AYAs, and older adults. For OS, death from any cause was considered an
event. LFS was defined as survival in CR after HCT. Relapse was defined as leukemia
recurrence. TRM was defined as death in CR. All outcomes were assessed from the date of
transplantation.
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The NMDP classification of HLA-matching status was used for URD recipients (well-
matched, partially matched, or mismatched) (Weisdorf D, 2008). Where information was
available, cytogenetic risk was classified as high-risk (t(4;11), t(9;22), t(8;14), hypodiploidy,
or near triploidy, or more than 5 cytogenetic abnormalities), normal (normal cytogenetics),
or other (any other abnormality) (Moorman AV, 2010; Moorman AV, 2007).
As a secondary objective, we evaluated whether the type of transplant center (adult versus
pediatric) was associated with OS for a subgroup of AYAs between 15–25 years of age. We
used several data sources to determine whether transplant centers were primarily adult or
pediatric transplant programs. First, we used information available from the CIBMTR and
the NMDP, where centers report their patients’ characteristics, including age. However,
some centers with distinct adult and pediatric programs report as one center to the CIBMTR
and/or NMDP. For these centers, we used data collected as part of a national CIBMTR
survey to designate centers as adult versus pediatric (Navneet Majhail, personal
communication). Furthermore, we also contacted each “combined center” to determine a)
whether these centers performed transplants exclusively for pediatric patients, adult patients,
or both; b) if both adults and children were transplanted, were there separate pediatric and
adult transplant teams; and c) the age cutoff that a center used to determine whether a patient
would be cared for by the adult or pediatric service. Based on information obtained from
these various above listed sources, centers were classified as adult or pediatric.
Statistical methods
Summaries of patient-, disease-, and treatment-related characteristics were produced for the
three age groups. The chi-square test was used to compare categorical variables, and the
Kruskal-Wallis test was used for continuous variables. Univariate probabilities of OS and
LFS were calculated using the Kaplan-Meier estimator (Kaplan, 1985). Probabilities of
relapse and TRM were estimated using a cumulative incidence function method (Gooley T,
1999). To evaluate changes in outcomes over time, we divided the cohort into three time
periods based on the year of transplantation (1990–1995–1996–2001, and 2002–2007).
Cox proportional hazards models were used to adjust for significant covariates while
comparing the three age groups. All factors were examined for proportional hazards using a
time-dependent covariate to appropriately model early versus later events. A backward
regression model selection technique was used to identify significant covariates to be
included in the models. The main effects tested in all multivariate analysis models were age
and time period of transplantation. Consistent with the primary study question, potential
interactions between age and time period were also examined. In addition to age and time
period of transplantation, the patient and disease characteristic covariates considered in the
multivariable models included gender, race/ethnicity, Karnofsky performance status, disease
status, cell of origin (T vs. B-cell), cytogenetic risk, and time from diagnosis to HCT. As
time from diagnosis to CR1 was confounded by disease status (CR1 vs. CR2), the two
covariates were combined for multivariable analysis (CR1 vs. CR2, duration of CR1 <36
months vs. CR2, duration of CR1 ≥ 36 months, CR2, duration of CR1 unknown).
For the subgroup analysis that focused on adult versus pediatric center comparison for
AYAs between 15–25 years of age, we describe the characteristics of patients transplanted
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at the two types of center. Univariate probabilities of OS, LFS, TRM and relapse were
analyzed as described above. Because of limited number of patients, we were not able to
perform multivariable analyses to study the association of center type with patient outcomes.
All computations were performed using the SAS statistical package (SAS Institute, Cary,
NC). All P-values are two sided.
Results
Patient characteristics
In total, 2668 patients with ALL in CR1 or CR2 reported to the CIBMTR from 1990–2007
met the study eligibility criteria, including 981 children, 1218 AYAs, and 469 older adults
(Table 1). From 1996–2007, transplant volume increased by 7% in children, 50% in AYAs,
and 180% in older adults. The proportions of patients receiving peripheral blood stem cell
transplants and of patients receiving HCT using well-matched URD HCT increased over
time in all three age groups. The proportions of Hispanic recipients increased among
children and AYAs over time (in children, 6% in 1990–1995 to 17% in 2002–2007, and in
AYAs, 4% in 1990–1995 to 15% in 2002–2007), but remained unchanged in older adults
(5% in 1990–1995 to 6% in 2002–2007).
Outcomes over time
Univariate analyses for OS, LFS, relapse, and TRM of children, AYAs and older adults over
time are presented in Table 2. Survival was inversely related to age, with older patients
having lower 5-year OS and LFS rates than AYAs, who in turn had lower OS and LFS rates
than children, particularly in the two most recent time periods. For all time periods, higher
TRM probability estimates were directly related to increasing age, with AYAs having higher
5-year TRM than children, and adults having higher TRM than AYAs. The probability of
relapse was similar across cohorts for each of the time periods.
Results for multivariate analyses for OS, LFS, relapse, and TRM are shown in Table 3. After
adjusting for patient and disease characteristics, older age was shown to be associated with
poorer survival (hazard ratio (HR) 2.04 for older adults and 1.57 for AYAs versus children,
p<0.001). No significant interactions were observed between age and time period. Figure 1
displays 5-year adjusted OS probabilities for each age group over time, highlighting that
overall survival for AYAs improved and did not lag behind any survival improvements in
the other age groups. Similar findings were observed for LFS and TRM, in which older
patients again had inferior outcomes compared with AYAs, who in turn had inferior
outcomes compared with children. Again, there was no significant interaction between age
and time period.
For the entire cohort, late relapse rates (>12 months from HCT) for AYAs were higher than
overall relapse rates for children (HR 2.1, p<0.001), whereas early relapse rates for AYAs
were not significantly different than overall relapse rates for children (HR 1.1, p=0.42). The
difference between overall relapse rates for older adults and those for children was of
borderline significance (HR 1.3, p=0.05). Relapse rates following HCT were not
significantly different in 2002–2007 when compared with 1990–1995 (HR 1.2, p=0.10).
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An analysis of outcomes stratified by donor type for the three age cohorts in the most recent
time period, 2002–2007, was also performed, with results presented in Table 4. In
unadjusted outcomes, children maintained superior survival outcomes to AYAs and older
adults, including recipients of both matched sibling and unrelated donor transplants. TRM
was higher in AYAs and in older adults than in children for both types of transplants.
Differences in pediatric versus adult centers for AYAs
Table 5 shows transplant characteristics for 15–25 year old patients who underwent HCT at
either a pediatric or adult transplant center. For this analysis there were 130 AYAs within
this age group transplanted at 46 pediatric centers, and 92 AYAs transplanted at 49 adult
centers. OS, LFS, relapse and TRM did not appear to differ by center type (Figure 2), but
sample size precluded formal statistical comparison with adjustment for relevant patient and
transplant characteristics.
There were several differences between pediatric and adult centers in baseline patient
characteristics and transplant techniques. AYAs of age 15–25 years at pediatric centers were
more likely to have a high pre-HCT Karnofsky Performance Status (78% with KPS ≥ 90 in
pediatric centers versus 66% in adult centers, p=0.005). In pediatric centers, patients had a
shorter interval from diagnosis to CR1 (p=0.003) and had a longer time from diagnosis to
transplant (p=0.02). AYAs transplanted at pediatric centers were more likely to receive bone
marrow grafts than AYAs at adult centers (57% versus 26%, p<0.001). AYAs transplanted
at pediatric centers were more likely to receive cyclosporine based graft-versus-host disease
(GVHD) prophylaxis (41% versus 21%, p<0.01) and were more likely to receive
cyclophosphamide/total body irradiation conditioning (78% versus 68%, p=0.04).
Discussion
Although survival improvements for AYAs with cancer in general have lagged behind
children and older adults, we found that survival after transplantation for AYAs improved
over time in parallel to younger patients and more favorably than older adults. The
observation that survival improvements in AYAs did not lag behind other age groups is
similar to findings from a recent study of outcomes following myeloablative transplantation
for acute myeloid leukemia [Majhail N, 2012]. Further, although sample size precluded a
formal comparison of outcomes for AYAs treated at pediatric versus adult transplant
centers, in our study survival rates appeared similar despite differences in patient selection
and transplantation techniques. Taken together, these data provide reassurance that AYAs
with ALL seem to be benefiting from survival improvements in HCT in similar ways to their
younger counterparts, and that treatment setting does not appear, at least preliminarily, to be
a major determinant of outcome.
However, our study does demonstrate broader observations about the influence of increasing
age upon outcomes following myeloablative transplantation for ALL. Across all time
periods, children maintained a survival advantage over AYAs and older adults. Further,
survival rates did not appear to improve in the older adult group over time. It appears that
some of the survival improvement over time in the younger age groups was attributable to
lower rates of TRM, especially in the early post-transplant period. These data are consistent
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with larger trends in improvements in supportive care leading to decreased TRM following
allogeneic HCT in general [Gooley T, 2010; Hahn T, 2013]. In the most recent time period,
TRM remained higher for AYAs and for older adults than for children, including recipients
of matched sibling donor transplants. This observation highlights the continued important
contribution of TRM to outcomes following myeloablative transplantation in AYAs and
older adults, even in the modern transplant era. In this study, we were not able to analyze
outcomes of GVHD or other potential contributors to TRM, which needs to be addressed by
future research. Another important observation was the lack of reduction over time in
relapse rates for any age group. This highlights the need for more research to investigate
novel methods to prevent relapse in these high risk patients.
The observation that TRM is an important determinant of survival following myeloablative
HCT for ALL is consistent with published data from large controlled trials. In the MRC/
ECOG study, the difference in survival between the donor and no-donor groups was
significant only in standard-risk patients because of the higher TRM (36%) in the high-risk
patients undergoing transplantation [Goldstone AH, 2008]. In this study, risk was defined in
part by age greater than or less than 35. The HOVON study did not categorize risk by age in
the same way as the MRC/ECOG study, but the authors did conclude that the greatest
benefit of myeloablative HCT for ALL in first CR was likely to be seen when TRM rates
were less than 20% [Cornelissen JJ, 2009]. An individual patient data meta-analysis that
included both of the above studies concluded that HCT for ALL in first CR was beneficial
only in patients younger than 35 years of age because of higher rates of TRM in older
patients [Gupta V, Blood 2013]. Within clinical trials, the reasons for differences in TRM as
a function of age are not entirely known and may relate to disease-related and age-related
biology.
In contrast to the above cited studies based on randomized controlled trials, our
observational study also highlights significant practice variation in transplantation
techniques for ALL. In pediatric versus adult treatment settings, we found differences in the
characteristics of patients being transplanted and the type of conditioning regimen, stem cell
source, and GVHD prophylaxis used. These are all key elements of the clinical practice of
HCT. Our study was not designed to assess the impact of these differences on outcomes.
While superficially these differences did not appear to impact the outcomes of 15–25 year
old AYAs undergoing transplant, larger studies would be needed to confirm this
observation. Whether these differences in practice patterns between pediatric and adult
centers have any impact more generally on outcomes following HCT for ALL is not known.
For example, characteristics of how patients come to transplant at pediatric versus adult
centers (time to CR1, time from diagnosis to transplant) may impact relapse rates following
transplantation, particularly if, over time, reduced intensity transplantation regimens are
used with increasing frequency in adult settings. As another example, while marrow grafts
are used more frequently in pediatric settings, perhaps because of the higher proportion of
non-malignant diseases transplanted in pediatric centers, marrow versus peripheral blood use
may affect post-transplant graft-versus-leukemia or GVHD rates in patients transplanted for
ALL [Anasetti C, 2012]. Additionally, the distinction between pediatric and adult treatment
programs is only one variable that impacts practice patterns [Lee SJ, 2008]. Whether
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outcomes are influenced by center-specific differences in transplant techniques among adult
centers or among pediatric centers is also not known.
Our study does have several limitations inherent in a retrospective analysis with registry-
level data. We were unable to address issues related to access to HCT, or issues related to
caregiver support, financial resources, medication and supportive care adherence, or other
factors that may influence outcomes following HCT for AYAs and other age groups. We
were also unable to address the issue of confounding due to selection, including the
possibility that differences in explicit or implicit criteria for transplantation might differ by
age group. For example, it is possible that younger patients may have been more likely to
have adverse prognostic features at the time of transplantation than older patients, given
differences in practice patterns in the pediatric versus adult settings. Finally, systematic
differences by age group in pre-transplant treatment might have affected relative outcomes
among patients who were included in this analysis. Differences in pre-HCT therapy could
conceivably affect TRM, as pediatric patients in our study had higher pre-HCT KPS scores
than AYA and adult patients, and the relative contributions of differences in pre-HCT
therapy vs host biological differences to this finding are not readily discernible with our
data. Differences in pre-HCT therapy could also contribute to relapse rates. Some of the
patients in the AYA group were likely treated on modified pediatric protocols and others on
adult protocols, and we were not able to determine which patients were treated on which
pre-HCT protocols with our available data.
Moving forward, additional studies will be needed to better understand reasons for persistent
differences in late TRM in relationship to increasing patient age. The impact of conditioning
regimen intensity on TRM and overall survival for comparable patients, the subject of an
ongoing multicenter trial [NCT01339910], also requires clarification. A retrospective
CIBMTR study of patients with Philadelphia chromosome negative ALL transplanted in
first or second complete remission suggested similar age-adjusted survival after reduced
intensity or full intensity conditioning [Marks DI, 2010]. In parallel, a more precise
understanding of relapse risk as a function of pre-HCT “adult-like” or “pediatric-like”
chemotherapy is also needed. After these issues are further clarified, individualized pre-HCT
calculators of TRM and relapse risk may become possible, similar to the recent development
of post-HCT calculators [Lee SJ, 2013], in turn facilitating the personalized application of
transplant strategies for this disease.
In conclusion, our study shows that improvements in survival among AYAs undergoing
allogeneic HCT for ALL parallel those seen among younger patients, and are more
favorable than those among older adults. However, our study also demonstrates persistent
survival disparities across increasing age groups that warrant further study.
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5-year adjusted overall survival probabilities for each age group over time (the lines in the
box represent survival probability and the ends of the box represent 95% confidence
intervals)
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Outcomes for AYAs 15–25 years of age transplanted between 2002 and 2007
(A) overall survival
(B) leukemia-free survival
(C) treatment related mortality
(D) relapse
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Table 2
Unadjusted probability of outcomes by time period and age group at 5-years after HCT
Outcome 1990–1995 1996–2001 2002–2007
Probability (95% CI) Probability (95% CI) Probability (95% CI)
Overall survival
 Children 49 (43–55) 53 (47–58) 58 (53–63)
 AYAs 34 (29–40) 34 (29–39) 43 (39–47)
 Older adults 41 (29–54) 22 (14–30) 36 (30–41)
Leukemia-free survival
 Children 47 (41–53) 33 (43–53) 53 (48–58)
 AYAs 33 (28–39) 31 (26–36) 38 (34–43)
 Older adults 41 (29–55) 19 (12–27) 33 (28–39)
Relapse
 Children 23 (18–28) 26 (21–31) 28 (24–33)
 AYAs 24 (19–29) 28 (23–33) 31 (27–35)
 Older adults 4 (0–10) 28 (20–37) 26 (21–31)
Treatment-related mortality
 Children 30 (25–36) 26 (22–31) 19 (15–23)
 AYAs 43 (37–49) 41 (36–46) 31 (27–35)
 Older adults 55 (42–68) 53 (44–63) 41 (36–47)
Abbreviations: AYAs – Adolescent and young adults; CI – confidence intervals
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Table 3
Multivariate analyses for outcomes by time period and age group
Variable Hazard Ratio 95% Confidence Intervals P-value
Overall survival€
Age group
 Children 1.00 - <0.001*
 AYAs 1.57 1.40–1.77 <0.001
 Older adults 2.04 1.75–2.39 <0.001
Year of transplantation
 1990–1995 1.00 - <0.001*
 1996–2001 (≤ 4 months)† 0.82 0.67–0.99 0.04
 1996–2001 (>4 months)† 1.21 1.01–1.46 0.04
 2002–2007 (≤ 4 months)† 0.44 0.36–0.54 <0.001
 2002–2007 (>4 months)† 1.12 0.94–1.33 0.22
Leukemia free survival¥
Age group
 Children 1.00 - <0.001*
 AYAs 1.50 1.34–1.69 <0.001
 Older adults 1.84 1.58–2.14 <0.001
Year of transplantation
 1990–1995 1.00 -
 1996–2001 (≤ 2 months)† 0.74 0.58–0.94 0.02*
 1996–2001 (>2 months)† 1.22 1.04–1.43 0.02
 2002–2007 (≤ 2 months)† 0.40 0.31–0.51 <0.001
 2002–2007 (>2 months)† 1.06 0.91–1.24 0.44
Relapse#
Age group
 Children 1.00 - <0.001*
 AYAs (≤ 12 months)† 1.08 0.89–1.32 0.42
 AYAs (>12 months)† 2.09 1.59–2.75 <0.001
 Older adults 1.28 1.00–1.63 0.05
Year of transplantation
 1990–1995 1.00 - 0.08*
 1996–2001 1.28 1.03–1.58 0.03
 2002–2007 1.18 0.97–1.45 0.10
Treatment related mortality
Age group
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Variable Hazard Ratio 95% Confidence Intervals P-value
 Children 1.00 - <0.001*
 AYAs 1.66 1.42–1.95 <0.001
 Older adults 2.37 1.94–2.88 <0.001
Year of transplantation
 1990–1995 1.00 - <0.001*
 1996–2001 (≤ 4 months)† 0.79 0.64–0.97 0.03
 1996–2002 (>4 months)† 1.28 0.96–1.71 0.09
 2002–2007 (≤ 4 months)† 0.42 0.34–0.52 <0.001




Non-proportional hazards; hazard ratio differed by time since transplantation (e.g., ≤ 4 months or >4 months for overall survival and treatment
related mortality)
€
Multivariable models adjusted for the following covariates: disease status, cell of origin, cytogenetic risk, and Karnofsky performance score at
transplant
¥
Multivariable models adjusted for the following covariates: disease status, cell of origin, cytogenetic risk, and Karnofsky performance score at
transplant
#
Multivariable models adjusted for the following covariates: disease status
$
Multivariable models adjusted for the following covariates: cytogenetic risk, interval from diagnosis to transplant, and Karnofsky performance
score at transplant
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Table 4
Unadjusted probability of outcomes by donor type and age group at 5-years after HCT for the most recent
cohort (2002–2007)
Outcome Matched Sibling Donor Unrelated Donor
Probability (95% CI) Probability (95% CI)
Overall survival
 Children 68 (56–81) 56 (50–62)
 AYAs 48 (38–59) 42 (37–47)
 Older adults 33 (24–46) 37 (30–44)
Leukemia-free survival
 Children 61 (49–75) 52 (46–58)
 AYAs 34 (34–54) 38 (33–43)
 Older adults 31 (23–43) 34 (28–41)
Relapse
 Children 34 (21–47) 27 (22–32)
 AYAs 31 (22–41) 31 (26–35)
 Older adults 29 (19–40) 24 (18–30)
Treatment-related mortality
 Children 5 (1–13) 21 (16–26)
 AYAs 25 (17–35) 32 (27–37)
 Older adults 39 (28–50) 42 (34–49)
Abbreviations: AYAs – Adolescent and young adults; CI – confidence intervals
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Table 5
Patient characteristics by center type (pediatric versus adult) for AYAs age 15–25 years who received a
myeloablative allogeneic HCT between 2002 and 2007
Characteristics Pediatric Center Adult Center P-value
N(%) N(%)
Number of patients 130 92
Number of centers 46 49
Age at HCT, years <0.001
 15–19 106 (82) 22 (24)
 20–25 24 (18) 70 (76)
KPS at HCT 0.005
 ≥ 90 101 (78) 61 (66)
 < 90 18 (14) 28 (30)
Disease status at HCT 0.18
 CR1 46 (35) 45 (49)
 CR2, CR1 duration <36 mos 29 (35) 36 (39)
 CR2, CR1 duration ≥ 36 mos 18 (14) 7 (8)
 CR2, CR1 duration unknown 7 (5) 4 (4)
Interval from diagnosis to CR1, months 0.003
 <1 54 (48) 21 (25)
 1–6 55 (49) 55 (65)
 ≤ 6 4 (4) 8 (10)
Time from diagnosis to HCT, months 0.019
 <6 26 (20) 30 (33)
 6–12 23 (18) 22 (24)
 ≥ 12 81 (62) 40 (43)
Cytogenetic risk 0.34
 High risk 35 (27) 17 (18)
 Normal 33 (25) 31 (34)
 Other 35 (27) 22 (24)
 Not tested/unknown 27 (21) 22 (24)
Graft type <0.001
 Bone Marrow 74 (57) 24 (26)
 Peripheral Blood 56 (43) 68 (74)
HLA match 0.11
 HLA-identical sibling 21 (16) 19 (21)
 Unrelated, well matched 68 (52) 49 (53)
 Unrelated, partially matched 26 (20) 22 (24)
 Unrelated, mismatched 12 (9) 1 (1)
 Unrelated, unknown degree of match 3 (2) 1 (1)






















Wood et al. Page 22
Characteristics Pediatric Center Adult Center P-value
N(%) N(%)
Conditioning 0.04
 TBI/Cy 102 (78) 63 (68)
 Cy/Bu 4 (3) 4 (4)
 TBI/etoposide 15 (12) 12 (13)
 TBI/other 8 (6) 5 (5)
 Other 1 (1) 8 (9)
GVHD prophylaxis <0.01
 CSA+ MTX +/− other 53 (41) 19 (21)
 FK506 + MTX +/− other 35 (27) 44 (48)
 T cell depletion 21 (16) 3 (3)
 Other 21 (16) 26 (28)
Abbreviations: AYAs – Adolescent and young adults; KPS – Karnofsky performance status; HCT – hematopoietic cell transplantation; CR –
complete remission; HLA – human leukocyte antigen; TBI – total body irradiation; Cy – cyclophosphamide; Bu – busulfan; GVHD – graft-versus-
host disease; CSA – cyclosporine; MTX – methotrexate
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